IPC will use the information you provide on this form to send you information about psoriasis. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by emailing info@psoriasiscouncil.org. By clicking the subscribe button, you agree that we may process your information in accordance with our privacy statement. We use Mailchimp and Memberclicks as our marketing automation platforms and you acknowledge the information you provide will be transferred to those platforms for processing in accordance with their privacy policy and terms.
Latest news Dermavant Announces FDA Approval for VTAMA® (Tapinarof) CreamMay 26, 2022Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years. Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib DataMay 16, 2022Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis. Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 PandemicMay 11, 2022IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis. New Corporate MemberMay 03, 2022IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member! More News